Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
21 nov. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
07 nov. 2023 10h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
27 oct. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
26 oct. 2023 16h30 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
17 oct. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
17 oct. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 août 2023 07h15 HE
|
Monte Rosa Therapeutics, Inc.
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023Received Orphan Drug Designation from the U.S. Food and Drug...
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
26 juil. 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
30 mai 2023 16h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...